Induction of protective and mucosal immunity against diphtheria by a immune stimulating complex (ISCOMS) based vaccine

Vaccine

Volumn 24, Issue 24, 2006, Pages 5201-5210

  Aguila, Antonio ^a   Donachie, Anne M ^a   Peyre, Marisa ^b   McSharry, Charles P ^a   Sesardic, Dorothea ^b   Mowat, Allan McI ^a  

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

Author keywords

Diphtheria; ISCOMS; Mucosal vaccination; Protective immunity

Indexed keywords

ALUMINUM; DIPHTHERIA TOXOID; DIPHTHERIA VACCINE; GAMMA INTERFERON; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; INTERLEUKIN 5; ISCOM; NEUTRALIZING ANTIBODY; QUIL A;

ACTIVE IMMUNIZATION; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY BLOOD LEVEL; ANTIBODY PRODUCTION; ARTICLE; CELLULAR IMMUNITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIPHTHERIA; DRUG FORMULATION; FEMALE; HUMORAL IMMUNITY; IMMUNOGENICITY; LYMPHOID TISSUE; MOUSE; MUCOSAL IMMUNITY; NONHUMAN; PRIORITY JOURNAL;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, INTRANASAL; ADMINISTRATION, ORAL; ANIMALS; ANTIBODIES, BACTERIAL; DIPHTHERIA TOXOID; FEMALE; GUINEA PIGS; IMMUNITY, MUCOSAL; IMMUNIZATION; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; ISCOMS; MICE; MICE, INBRED BALB C;

EID: 33744515008     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2006.03.081     Document Type: Article

References (39)

1. Kelly C., and Efstratiou A. Seventh International Meeting of the European Laboratory Working Group on Diphtheria. Euro Surveill 8 10 (2003) 189-195
2. George R.C., Beloborodov V.B., and Efstratiou A. Diphtheria in the 1990s: return of an old adversary. Clin Microbiol Infect 1 2 (1995) 139-145
3. Galazka A. The changing epidemiology of diphtheria in the vaccine era. J Infect Dis 181 Suppl 1 (2000) S2-S9
4. Gandon S., Mackinnon M.J., Nee S., and Read A.F. Imperfect vaccines and the evolution of pathogen virulence. Nature 414 6865 (2001) 751-756
5. Clements C.J., and Griffiths E. The global impact of vaccines containing aluminium adjuvants. Vaccine 20 Suppl 3 (2002) S24-S33
6. Martin-Munoz M.F., Pereira M.J., Posadas S., Sanchez-Sabate E., Blanca M., and Alvarez J. Anaphylactic reaction to diphtheria-tetanus vaccine in a child: specific IgE/IgG determinations and cross-reactivity studies. Vaccine 20 27-28 (2002) 3409-3412
7. Alpar H.O., Eyles J.E., Williamson E.D., and Somavarapu S. Intranasal vaccination against plague, tetanus and diphtheria. Adv Drug Deliv Rev 51 1-3 (2001) 173-201
8. Schröder U., and Svenson S.B. Nasal and parenteral immunizations with diphtheria toxoid using monoglyceride/fatty acid lipid suspensions as adjuvants. Vaccine 17 15-16 (1999) 2096-2103
9. Fromen-Romano C., Drevet P., Robert A., Menez A., and Leonetti M. Recombinant Staphylococcus strains as live vectors for the induction of neutralizing anti-diphtheria toxin antisera. Infect Immun 67 10 (1999) 5007-5011
10. McNeela E.A., O'Connor D., Jabbal-Gill I., et al. A mucosal vaccine against diphtheria: formulation of cross reacting material (CRM(197)) of diphtheria toxin with chitosan enhances local and systemic antibody and Th2 responses following nasal delivery. Vaccine 19 9-10 (2000) 1188-1198
11. Miyaji E.N., Mazzantini R.P., Dias W.O., et al. Induction of neutralizing antibodies against diphtheria toxin by priming with recombinant Mycobacterium bovis BCG expressing CRM(197), a mutant diphtheria toxin. Infect Immun 69 2 (2001) 869-874
12. van der Lubben I.M., Kersten G., Fretz M.M., Beuvery C., Coos Verhoef J., and Junginger H.E. Chitosan microparticles for mucosal vaccination against diphtheria: oral and nasal efficacy studies in mice. Vaccine 21 13-14 (2003) 1400-1408
13. Garside P., and Mowat A.McI. Oral tolerance. Semin Immunol 13 3 (2001) 177-185
14. Mowat AMcI, Faria AM, Weiner HL. Oral tolerance: basic mechanisms and clinical implications. In: Mestecky J, Bienenstock J, Lamm ME, Strober W, McGhee JR, Mayer L., editors. Mucosal immunology. 3rd ed. San Diego: Academic Press; 2005. p. 487-538.
15. Mowat A.McI., Smith R.E., Donachie A.M., Furrie E., Grdic D., and Lycke N. Oral vaccination with immune stimulating complexes. Immunol. Lett. 65 (1999) 133-140
16. Smith R.E., Donachie A.M., and Mowat A.McI. Immune stimulating complexes as mucosal adjuvants. Immunol Cell Biol 76 (1998) 263-269
17. Hu K.F., Lovgren-Bengtsson K., and Morein B. Immunostimulating complexes (ISCOMs) for nasal vaccination. Adv Drug Deliv Rev 51 1-3 (2001) 149-159
18. Mowat A.McI., and Reid G. The preparation of immune stimulating complexes (ISCOMS) as adjuvants for local and systemic immunisation with protein antigens. In: Coligan J.E., Kruisbeek A.M., Margulies D., Shevach E., and Strober W. (Eds). Current protocols in immunology (2001), John Wiley and Sons Inc., New York 2.11.11-2.11.12
19. Mowat A.McI., Maloy K.J., and Donachie A.M. Immune stimulating complexes as adjuvants for inducing local and systemic immunity after oral immunization with protein antigens. Immunology 80 4 (1993) 527-534
20. Maloy K.J., Donachie A.M., and Mowat A.McI. Induction of Th1 and Th2 CD4+ T cell responses by oral or parenteral immunization with ISCOMS. Eur J Immunol 25 (1995) 2835-2841
21. Winsnes R., Sesardic D., Daas A., and Rigsby P. A Vero cell method for potency testing of diphtheria vaccines. Dev Biol 111 (2002) 141-148
22. Garside P., Steel M., Worthey E.A., et al. Th2 cells are subject to high dose oral tolerance and are not essential for its induction. J Immunol 154 (1995) 5649-5655
23. Sjolander A., Drane D., Maraskovsky E., et al. Immune responses to ISCOM formulations in animal and primate models. Vaccine 19 17-19 (2001) 2661-2665
24. Coulter A., Harris R., Davis R., et al. Intranasal vaccination with ISCOMATRIX adjuvanted influenza vaccine. Vaccine 21 9-10 (2003) 946-949
25. Morein B., Ekstrom J., and Lovgren K. Increased immunogenicity of a non-amphipathic protein (BSA) after inclusion into ISCOMS. J Immunol Meth 128 (1990) 177
26. Hsu S.C., Schadeck E.B., Delmas A., Shaw M., and Steward M.W. Linkage of a fusion peptide to a CTL epitope from the nucleoprotein of measles-virus enables incorporation into iscoms and induction of CTL responses following intranasal immunization. Vaccine 14 12 (1996) 1159-1166
27. Lövgren K. The serum antibody response distributed in subclasses and isotypes after intranasal and subcutaneous immunization with influenza virus immunostimulating complexes. Scand J Immunol 27 (1988) 241-245
28. Mowat A.McI., Donachie A.M., Jägewall S., et al. CTA1-DD-ISCOMS; a novel, rationally designed combined mucosal vaccine adjuvant effective with nanogram doses of antigen. J Immunol 167 (2001) 3398-3405
29. McGhee J.R., Czerkinsky C., and Mestecky J. Mucosal vaccines: an overview. In: Ogra P.L., Mestecky J., Lamm M.E., Strober W., McGhee J.R., and Bienenstock J. (Eds). Mucosal immunology. 2nd ed. (1999), Academic Press, San Diego 741-757
30. Eriksson K., and Holmgren J. Recent advances in mucosal vaccines and adjuvants. Curr Opin Immunol 14 5 (2002) 666-672
31. Rydell N., and Sjoholm I. Oral vaccination against diphtheria using polyacryl starch microparticles as adjuvant. Vaccine 22 9-10 (2004) 1265-1274
32. McNeela E.A., Jabbal-Gill I., Illum L., et al. Intranasal immunization with genetically detoxified diphtheria toxin induces T cell responses in humans: enhancement of Th2 responses and toxin-neutralizing antibodies by formulation with chitosan. Vaccine 22 8 (2004) 909-914
33. Yasuda Y., Isaka M., Taniguchi T., et al. Frequent nasal administrations of recombinant cholera toxin B subunit (rCTB)-containing tetanus and diphtheria toxoid vaccines induced antigen-specific serum and mucosal immune responses in the presence of anti-rCTB antibodies. Vaccine 21 21-22 (2003) 2954-2963
34. Isaka M., Komiya T., Takahashi M., et al. Recombinant cholera toxin B subunit (rCTB) as a mucosal adjuvant enhances induction of diphtheria and tetanus antitoxin antibodies in mice by intranasal administration with diphtheria-pertussis-tetanus (DPT) combination vaccine. Vaccine 22 23-24 (2004) 3061-3068
35. Isaka M., Yasuda Y., Kozuka S., et al. Induction of systemic and mucosal antibody responses in mice immunized intranasally with aluminium-non-absorbed diphtheria toxoid together with recombinant cholera toxin B subunit as an adjuvant. Vaccine 18 (2000) 743-751
36. Benahmeida E.T.S., Potter C.W., Gregoriadis G., Adithan C., and Jennings R. IgG subclass response and protection against challenge following immunization of mice with various influenza-a vaccines. J Med Microbiol 40 4 (1994) 261-269
37. Ahmeida E., Jennings R., Erturk M., and Potter C.W. The IgA and subclass IgG responses and protection in mice immunized with influenza antigens administered as iscoms, with FCA, AlOH or as infectious virus. Arch Virol 125 1-4 (1992) 71-86
38. Heeg K., Kuon W., and Wagner H. Vaccination of Class I major histocompatibility complex (MHC)-restricted murine CD8+ cytotoxic T lymphocytes toward soluble antigen: immunostimulating complexes enter the Class I MHC-restricted antigen pathway and allow sensitization against the immunodominant peptide. Eur J Immunol 21 (1991) 1523-1527
39. Mowat A.McI., Donachie A.M., Reid G., and Jarrett O. Immune stimulating complexes containing Quil A and protein antigen prime Class I MHC-restricted T lymphocytes in vivo and are active by the oral route. Immunology 72 (1991) 317-322